

# Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer

Jaime Rubio, Ion Cristóbal, Andrea Santos, Cristina Caramés, Melani Luque, Marta Sanz-Alvarez, Sandra Zazo, Juan Madoz-Gúrpide, Federico Rojo and Jesús García-Foncillas

**Table S1.** Clinical and molecular characteristics of a series of 121 LARC patients.

		No. (%)	
<b>Sex</b>			
	Male	73	(60.3)
	Female	48	(39.7)
<b>Age</b>			
	<60	40	(33.1)
	≥60	81	(66.9)
<b>ECOG<sup>1</sup></b>			
	0	81	(66.9)
	1-2	40	(33.1)
<b>Site of primary tumor</b>			
	Rectum	121	(100)
<b>Clinical stage pre-CRT<sup>2</sup></b>			
	II	9	(7.4)
	III	112	(92.6)
<b>Grade pre-CRT</b>			
	Low	40	(35.7)
	Moderate-High	72	(64.3)
<b>ypT<sup>3</sup></b>			
	0	16	(13.2)
	1	16	(13.2)
	2	38	(31.4)
	3	44	(36.4)
	4	4	(3.3)
	x	3	(2.5)
<b>ypN<sup>4</sup></b>			
	0	91	(75.2)
	1	26	(21.5)
	2	4	(3.3)
<b>Pathological stage</b>			
	yp0	16	(13.2)
	ypI	43	(35.5)
	ypII	32	(26.5)
	ypIII	30	(24.8)
<b>Neoadjuvant CRT</b>			
	RT + 5-FU based	121	(100)
<b>Recurrence</b>			
	No	95	(78.5)
	Yes	26	(21.5)

<sup>1</sup>ECOG= Eastern Cooperative Oncology Group; <sup>2</sup>CRT= Chemoradiotherapy; <sup>3</sup>ypT= tumor size after CRT; <sup>4</sup>ypN= pathological lymph node after CRT.

**Table S2.** Univariate and multivariate analyses of factors predictive of event-free survival in the cohort of 121 LARC patients.

	Univariate EFS <sup>1</sup> analysis				Multivariate EFS Cox analysis			
	HR <sup>3</sup>	95% CI <sup>2</sup>		<i>p</i>	HR	95% CI		<i>p</i>
		Lower	Upper			Lower	Upper	
Gender				0.696				-
Male	1.000							
Female	0.820	0.303 to 2.219			-	-		
Age				0.201				-
<60	1.000							
≥60	2.255	0.648 to 7.851			-	-		
Pathological stage				<b>0.028</b>				0.492
0-I	1.000				1.000			
II-III	3.519	1.145 to 10.814			1.631	0.404 to 6.579		
ypT <sup>4</sup>				0.100				-
0-2	1.000							
3-4	2.306	0.852 to 6.243			-	-		
ypN <sup>5</sup>				<b>0.004</b>				0.066
N-	1.000				1.000			
N+	4.045	1.550 to 10.522			3.075	0.930 to 10.171		
ECOG <sup>6</sup>				0.349				-
0	1.000							
1-2	1.586	0.603 to 4.171			-	-		
MiR-19b				<b>0.035</b>				<b>0.044</b>
High	1.000				1.000			
Low	0.258	0.073 to 0.910			0.268	0.074 to 0.965		

<sup>1</sup>EFS: event-free survival; <sup>2</sup>CI: confidence interval; <sup>3</sup>HR: Hazard ratio; <sup>4</sup>ypT: tumor size after chemoradiotherapy (CRT); <sup>5</sup>ypN: pathological lymph node after CRT; <sup>6</sup>ECOG: Eastern Cooperative Oncology Group.

**Table S3.** Association between miR-19b and *PPP2R5E* expression levels in LARC patients.

	No. Cases	MiR-19b low (%)		MiR-19b high (%)		<i>p</i>
<i>PPP2R5E</i>	63	24		39		<0.001
Low	48	12	(50)	36	(92.3)	
High	15	12	(50)	3	(7.7)	

**Table S4.** Association between pathological response to neoadjuvant CRT and *PPP2R5E* expression in LARC patients.

Response	No. Cases	Response to neoadjuvant CRT <sup>1</sup>				<i>p</i>
		Responders <sup>2</sup> (%)		Non-Responders <sup>3</sup> (%)		
<i>PPP2R5E</i> expression	63	26		37		<b>0.022</b>
Low	48	16	(33.3)	32	(66.7)	
High	15	10	(66.7)	5	(33.3)	

<sup>1</sup>CRT: chemoradiotherapy; <sup>2</sup>Responders: moderate or complete pathological response; <sup>3</sup>Non-Responders: poor or minimal pathological response.